vigabatrin (sabril) Report issue

Small molecule Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Vigabatrin is an anticonvulsant chemically unrelated to other anticonvulsants. Vigabatrin prevents the catabolism of GABA by irreversibly inhibiting the enzyme GABA transaminase. It is an analog of GABA, but it is not a receptor agonist. However, vigabatrin is not a potent inhibitor of GABA-T with a Ki of 10 mM. Vigabatrin increases brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the CNS, by irreversibly inhibiting enzymes that catabolize GABA (gamma-aminobutyric acid transaminase, GABA-T). Duration of action is determined by rate of GABA-T re-synthesis. Vigabatrin may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels. Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active. Vigabatrin is sold under the trade name SABRIL, it is indicated as adjunctive therapy for adults and pediatric patients 10 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss.   NCATS

Chemistry

  • SMILES: NC(CCC(O)=O)C=C
  • InChIKey: PJDFLNIOAUIZSL-UHFFFAOYSA-N
  • Mol. Mass: 129.157
  • ALogP: 0.36
  • ChEMBL Molecule:
    vigabatrin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.6432 - $0.6940

United States

$104.6874 - $143.9146
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(+/-)-4-amino-5-hexenoic acid | 4-amino-5-hexenoic acid | cpp-109 | gamma vinyl gaba | gamma-vinyl gaba | gamma-vinyl-gamma-aminobutyric acid | gvg | mdl-71754 | sabril | vigabatrin | vigabatrina | vigabatrine | vigabatrin hcl | vigabatrin hydrochloride | vigabatrinum | vinyl gamma-aminobutyric acid

Organizations (65)

Research & Development (38)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (28)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (4)


 

Cocaine-Related Disorders

Epilepsy (approved 2009)

Epilepsy, Complex Partial

Spasms, Infantile

Experimental Indications - Clinical Trial Phases 1-4 (18)


 

Alcoholism (Phase 2)

Cocaine-Related Disorders (Phase 2/Phase 3)

Coma (Phase 2)

Epilepsy (Phase 4)

Glucose Intolerance (Phase 2)

Hyperinsulinism (Phase 2)

Hypertension (Phase 2)

Insulin Resistance (Phase 2)

Intellectual Disability (Phase 4)

Methamphetamine (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Obesity (Phase 2)

Seizures (Phase 4)

Spasms, Infantile ()

Status Epilepticus (Phase 2)

Therapeutic Equivalency (Phase 1)

Tourette Syndrome (Phase 1/Phase 2)

Tuberous Sclerosis (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial Organizations: 38

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue